The HTRA1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population originating from the Jurkat T lymphocyte line, engineered to ablate HTRA1 function. By employing a polyclonal knockout strategy, this model introduces diverse genetic disruptions across the cell population, reducing bias associated with single-cell cloning. This product serves as a versatile foundation for studies in signal transduction, cancer research, and immunology.
Jurkat cells are a widely utilized human T lymphocyte line derived from an acute T cell leukemia patient. These suspension cells are characterized by their active T cell receptor (TCR) signaling, robust proliferation, and well-defined apoptosis pathways, making them a standard model for T cell biology. The Jurkat background offers a physiologically relevant environment to assess how HTRA1 loss impacts TCR-mediated activation, cytokine production, and cell death mechanisms.
HTRA1 encodes a secreted serine protease that cleaves extracellular matrix components and critically modulates transforming growth factor-beta (TGF-beta) signaling. It processes TGF-beta ligands such as TGF-beta1 and TGF-beta2, affecting downstream phosphorylation of Smad2/3 and expression of targets including fibronectin, aggrecan, and amyloid precursor protein (APP). HTRA1 activity is regulated by p53, DNA damage, and cellular stress, and the protease interacts with alpha-2-macroglobulin and PDZ domain-containing proteins. Consequently, HTRA1 integrates signals across the TGF-beta/Smad, MAPK/ERK, and PI3K/AKT pathways, governing cellular proliferation, apoptosis, and differentiation.
In Jurkat T cells, disruption of HTRA1 abolishes its proteolytic regulation of TGF-beta ligands, leading to enhanced TGF-beta pathway activity and altered apoptotic and proliferative responses. As HTRA1 has been implicated as a tumor suppressor, this knockout model is particularly valuable for examining its role in leukemic cell survival and immune cell function. The polyclonal knockout population mirrors the genetic diversity found in tumor environments, facilitating more representative functional analyses.
Researchers can leverage this HTRA1 knockout product to investigate HTRA1 substrate repertoire, screen for TGF-beta pathway modulators, and analyze tumor suppressor mechanisms in T lymphocytes. Common experimental approaches include Western blotting for phospho-Smad2/3, RT-qPCR of TGF-beta target genes, Annexin V/PI apoptosis assays, flow cytometry for surface markers, and ELISA for secreted cytokines. For additional details on product validation and experimental protocols, please contact Ascent Research.
